NCT04062032 is a Phase 2 clinical trial of Aspirin 81 mg in Melanoma (Skin), sponsored by University of Utah.

Who is sponsoring NCT04062032?

NCT04062032 is sponsored by University of Utah.

What drugs are being tested in NCT04062032?

Interventions in NCT04062032: Aspirin 81 mg, Aspirin 325mg.

What condition does NCT04062032 study?

NCT04062032 studies Melanoma (Skin).

Is NCT04062032 still recruiting?

NCT04062032 is currently completed. Last updated 18 February 2022.

Last reviewed 2022-02-18 · How we verify

NCT04062032

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

Completed Phase 2 Last updated 18 February 2022

What this trial tests

Phase 2 trial testing Aspirin 81 mg in Melanoma (Skin) in 41 participants. Completed in 27 February 2019.

Timeline

27 September 2016

Primary endpoint
27 February 2019

27 February 2019

Quick facts

Lead sponsor	University of Utah
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	41
Start date	27 September 2016
Primary completion	27 February 2019
Estimated completion	27 February 2019
Sites	1 location across United States

Drugs / interventions tested

Aspirin 81 mg — full drug profile →
Aspirin 325mg — full drug profile →

Conditions studied

Melanoma (Skin) — all drugs for Melanoma (Skin) →

Sponsor

University of Utah

Who can join

18 and older, any sex, with Melanoma (Skin). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open label phase II pilot study assessing the metabolomic and inflammatory effects of oral aspirin (ASA) in human subjects at risk for melanoma.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives.
Pellerin L, Carrié L, Dufau C, Nieto L, et al · · 2020 · cited 65× · PMID 33121001 · DOI 10.3390/cancers12113147
Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.
Fu L, Jin W, Zhang J, Zhu L, et al · · 2022 · cited 47× · PMID 35256933 · DOI 10.1016/j.apsb.2021.09.006
Metabolic reprogramming in cancer and senescence.
Zhang Y, Tang J, Jiang C, Yi H, et al · · 2025 · cited 13× · PMID 40046406 · DOI 10.1002/mco2.70055
ASA Suppresses PGE<sub>2</sub> in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma.
Varedi A, Rahman H, Kumar D, Catrow JL, et al · · 2020 · cited 9× · PMID 31906519 · DOI 10.3390/ph13010007
Targeting AMPK for Cancer Therapy: Metabolic Reprogramming as a Therapeutic Strategy.
Hong M, Baek JH. · · 2025 · PMID 41050082 · DOI 10.32604/or.2025.067487
Updates in clinical trial-explored chemopreventive agents for cutaneous melanoma: mechanisms affecting melanocytes.
Ghajar-Rahimi G, Yusuf N. · · 2025 · PMID 40376946 · DOI 10.1080/20450885.2025.2505400

Verify or expand the search:

Other trials of Aspirin 81 mg

Trials testing the same drug.

NCT06468202 — Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL · Phase 4 · recruiting
NCT04243122 — Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients · Phase 2 · completed
NCT04479072 — Aspirin and Preeclampsia · Phase 4 · recruiting
NCT04153760 — Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity · EARLY_PHASE1 · completed
NCT04295850 — Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy) · completed

Other recruiting trials for Melanoma (Skin)

Currently open trials in the same condition.

NCT06643286 — Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma · NA · recruiting
NCT06298734 — High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial · NA · recruiting
NCT05704647 — Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases · Phase 2 · recruiting
NCT05492682 — START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer · Phase 1 · active not recruiting
NCT05649683 — Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors · NA · recruiting

Other University of Utah trials

Trials by the same sponsor.

NCT07515755 — Supplemental Oxygen and Oxygen Desaturations in Colonoscopies · NA · not yet recruiting
NCT07225426 — Personalizing Financial Incentives · NA · recruiting
NCT06716411 — Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness · NA · recruiting
NCT07246538 — Positive Airway Pressure (PAP) System Evaluation in Volunteers · NA · not yet recruiting
NCT04208984 — Diversion Device With Breath Control · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04062032 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Utah
Last refreshed: 18 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04062032.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing